• Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Unspecified (DepMap=ACH-001959).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (DepMap=ACH-001959).
  

PubMed=1355757; DOI=10.1002/ijc.2910520217
Shimizu Y., Demetris A.J., Gollin S.M., Storto P.D., Bedford H.M., Altarac S., Iwatsuki S., Herberman R.B., Whiteside T.L.
Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.
Int. J. Cancer 52:252-260(1992)

CLPUB00275
Zach S., Birgin E., Ruckert F.
Primary cholangiocellular carcinoma cell lines.
J. Stem Cell Res. Transplant. 2:1013-1013(2015)

PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737
Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H., Bardeesy N.M.
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Cancer Discov. 6:727-739(2016)

PubMed=31109923; DOI=10.1158/2159-8290.CD-19-0182; PMCID=PMC6677584
Goyal L., Shi L., Liu L.Y., Fece de la Cruz F., Lennerz J.K., Raghavan S., Leschiner I., Elagina L., Siravegna G., Ng R.W.S., Vu P., Patra K.C., Saha S.K., Uppot R.N., Arellano R.S., Reyes S., Sagara T., Otsuki S., Nadres B., Shahzade H.A., Dey-Guha I., Fetter I.J., Baiev I., Van Seventer E.E., Murphy J.E., Ferrone C.R., Tanabe K.K., Deshpande V., Harding J.J., Yaeger R.D., Kelley R.K., Bardelli A., Iafrate A.J., Hahn W.C., Benes C.H., Ting D.T., Hirai H., Getz G., Juric D., Zhu A.X.-X., Corcoran R.B., Bardeesy N.M.
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.
Cancer Discov. 9:1064-1079(2019)

PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155
Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y., Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S., Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.
Development and characterization of human primary cholangiocarcinoma cell lines.
Am. J. Pathol. 192:1200-1217(2022)

PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448
Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L., Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J., Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L., Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J., Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E., Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W., Vazquez F., Getz G., Bardeesy N.M.
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets.
bioRxiv 2024:07.04.601970-07.04.601970(2024)